drugset / Trial / NCT03397953

Vinorelbine for Recurrent ACLC

NCT03397953 ↗

Phase 2 Completed 20 enrolled Children's Cancer Group, China
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.

Timeline

Start
2016-11
Primary completion
2022-07
Completion
2022-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinorelbine Small molecule 25 mg/m2 —